Patents by Inventor Gregory Hinkle

Gregory Hinkle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190216845
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.
    Type: Application
    Filed: February 5, 2019
    Publication date: July 18, 2019
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof
    Patent number: 10344278
    Abstract: The invention relates to polynucleotide agents targeting the Serpinc1 (AT3) gene, and methods of using such polynucleotide agents to inhibit expression of Serpinc1 and to treat subjects having a bleeding disorder, e.g., a hemophilia.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 9, 2019
    Assignee: Genzyme Corporation
    Inventor: Gregory Hinkle
  • Organic compositions to treat HSF1-related diseases
    Patent number: 10287582
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: May 14, 2019
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
    Publication number: 20190119674
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
    Type: Application
    Filed: August 2, 2018
    Publication date: April 25, 2019
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Gregory Hinkle, Alfica Sehgal
  • GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
    Publication number: 20190106694
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 11, 2019
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 10238749
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 26, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin Maier, Stuart Milstein
  • Compositions and methods for inhibiting expression of transthyretin
    Patent number: 10240152
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 26, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Gregory Hinkle, Rene Alvarez, Stuart Milstein, Qingmin Chen
  • Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
    Patent number: 10231988
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: March 19, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF
    Publication number: 20190024088
    Abstract: The invention relates to polynucleotide agents targeting Factor XII (F12) gene, and methods of using such polynucleotide agents to inhibit expression of Factor XII and to treat subjects having a Factor XII-associated disease, e.g., heredity angioedema (HAE), prekallikrein deficiency, malignant essential hypertension, hypertension, end stage renal disease, or Fletcher Factor Deficiency.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Applicant: Alnylam Phaarmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
    Publication number: 20180371465
    Abstract: The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 27, 2018
    Inventor: Gregory Hinkle
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20180355362
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: August 20, 2018
    Publication date: December 13, 2018
    Inventors: Antonin De Fougerolles, John Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180346910
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 6, 2018
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
    Publication number: 20180282725
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
    Type: Application
    Filed: December 19, 2017
    Publication date: October 4, 2018
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180273955
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.
    Type: Application
    Filed: June 7, 2018
    Publication date: September 27, 2018
    Inventors: Kevin Fitzgerald, Huilei Xu, Gregory Hinkle
  • PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180273947
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such RNAi agents to inhibit expression of a PD-L1 gene and methods of treating subjects having a PD-L1-associated disorder.
    Type: Application
    Filed: August 22, 2016
    Publication date: September 27, 2018
    Inventor: Gregory Hinkle
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 10081811
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: September 25, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Antonin De Fougerolles, John Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Compositions and methods for inhibiting expression of the LECT2 gene
    Patent number: 10077444
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 18, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kevin Fitzgerald, Alfica Sehgal, Brian Bettencourt, Gregory Hinkle
  • XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180216114
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting a xanthine dehydrogenase (XDH) gene, and methods of using such double stranded RNAi agents to inhibit expression of an XDH gene and methods of treating subjects having an XDH-associated disease.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 2, 2018
    Inventors: Kevin Fitzgerald, Gregory Hinkle, Timothy Ryan Mooney
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10030244
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: July 24, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
    Publication number: 20180201936
    Abstract: The invention relates to polynucleotide agents targeting a Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such polynucleotide agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Inventor: Gregory Hinkle